This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimada, Y. Articles by Imamura, M. Search for Related Content PubMed PubMed Citation Articles by Shimada, Y. Articles by Imamura, M.

Clinical Significance of Dysadherin Expression in Gastric Cancer Patients

¹ Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan; ² Pathology Division, National Cancer Center Research Institute, Tokyo, Japan; and ³ Department of Pathology, Keio University, Tokyo, Japan

Purpose: Dysadherin, a cancer-associated cell membrane glycoprotein, has been reported to down-regulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in gastric cancer, we examined dysadherin and E-cadherin expression in gastric cancer patients.

Experimental Design: Dysadherin and E-cadherin expression were evaluated in 276 gastric cancer patients by immunohistochemistry, and the results were compared with the clinicopathological findings of the subjects.

Results: Dysadherin was not expressed in normal gastric epithelium. Both dysadherin and E-cadherin were localized to the cell membrane. Dysadherin expression was sometimes largely localized to infiltrating tumor cells or cells dissociating. Ninety gastric cancer patients (32.6%) were positive for dysadherin, and 151 patients (54.7%) showed preservation of E-cadherin expression. Expression of dysadherin was associated with moderately differentiated carcinoma and hematogenous metastasis, whereas reduced expression of E-cadherin showed an association with poorly differentiated carcinoma and peritoneal dissemination. As a result, dysadherin positivity and reduced E-cadherin expression were associated with a poor prognosis. In addition, patients with both dysadherin positivity and reduced E-cadherin had the worst prognosis. Multivariate analysis revealed that reduced E-cadherin expression was an independent prognostic factor, but dysadherin expression was not.

Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis and the mode of metastasis in gastric cancer patients. Patients with dysadherin positivity have a higher risk of hematogenous metastasis, whereas patients with reduced E-cadherin expression have an increased risk of peritoneal dissemination.

This article has been cited by other articles:

				T. J. Miller and P. B. Davis FXYD5 modulates Na+ absorption and is increased in cystic fibrosis airway epithelia Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L654 - L664. [Abstract] [Full Text] [PDF]

				M. Higashiyama, T. Ito, E. Tanaka, and Y. Shimada Prognostic Significance of Osteopontin Expression in Human Gastric Carcinoma Ann. Surg. Oncol., December 1, 2007; 14(12): 3419 - 3427. [Abstract] [Full Text] [PDF]

				J. H. Lee, S.-H. Kim, L.-H. Wang, Y.-L. Choi, Y. C. Kim, J. H. Kim, T. S. Park, Y.-C. Hong, and Y. K. Shin Clinical Significance of CD99 Down-Regulation in Gastric Adenocarcinoma Clin. Cancer Res., May 1, 2007; 13(9): 2584 - 2591. [Abstract] [Full Text] [PDF]

				J.-S. Nam, M.-J. Kang, A. M. Suchar, T. Shimamura, E. A. Kohn, A. M. Michalowska, V. C. Jordan, S. Hirohashi, and L. M. Wakefield Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res., July 15, 2006; 66(14): 7176 - 7184. [Abstract] [Full Text] [PDF]

				K. Geering FXYD proteins: new regulators of Na-K-ATPase Am J Physiol Renal Physiol, February 1, 2006; 290(2): F241 - F250. [Abstract] [Full Text] [PDF]